翔宇医疗收盘上涨2.15%，滚动市盈率113.89倍，总市值98.88亿元

Group 1 - The core business of the company is the research, production, and sales of rehabilitation medical devices, with a wide range of products including rehabilitation therapy, training, care, assistive devices, assessment, traditional Chinese medicine treatment, health maintenance, medical beauty, and home rehabilitation [2] - As of March 31, 2025, the company had 5,895 shareholders, an increase of 559 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's stock closed at 61.8 yuan on August 25, with a rolling price-to-earnings (PE) ratio of 113.89, significantly higher than the industry average PE of 56.14 [1][3] Group 2 - In the latest quarterly report for Q1 2025, the company achieved a revenue of 186 million yuan, a year-on-year increase of 10.02%, while net profit was 22.95 million yuan, reflecting a year-on-year decrease of 41.26% [3] - The company has received multiple awards for its projects, including first prizes for various rehabilitation technology projects from the Chinese Rehabilitation Medicine Association and other organizations, highlighting its innovation and contribution to the field [2]